Aprotinin PSUSA ends in 'maintenance': what a quiet outcome tells PV teams

What happened

On 30 October 2026 the EMA published the outcome of the periodic safety update report single assessment (PSUSA) for aprotinin. The result is 'maintenance': the marketing authorisations of the nationally authorised aprotinin products stay as they are. The agency also published a list of the products concerned.

The records give no further detail on the assessment itself. They do not say which safety questions were examined, whether any data were flagged for follow-up, or what the underlying reports contained. Anything beyond the outcome and the product list is not yet known from the published summary, and teams should read the full PSUSA documentation on the EMA page before drawing conclusions.

What 'maintenance' does and does not mean

A PSUSA pools periodic safety update reports for products containing the same active substance, so one EU-wide assessment replaces separate national reviews. The possible regulatory outcomes run from maintenance through variation to suspension or revocation. Maintenance is the least disruptive of these. It means the assessment did not lead to a change in the terms of the marketing authorisation.

It is not a statement that the product carries no risk, and it does not close the file. Routine pharmacovigilance, risk minimisation and the next scheduled reporting cycle continue as before. For marketing authorisation holders, the practical point is that no new product-information or conditions-related action should follow from this outcome. They should still confirm that against the published documents rather than assume it.

Quiet outcomes, louder signals

Aprotinin was not the only maintenance outcome posted that day. EMA published PSUSA results with the same outcome for gliclazide, tenoxicam, nitrofurantoin (including nitrofurantoin/pyridoxine hydrochloride) and cystine/pyridoxine hydrochloride. Taken together, these show how most periodic reviews end: with the existing benefit-risk position intact and little public drama.

The same week produced a sharper contrast. According to EMA and AIFA, PRAC at its October meeting opened a referral on flupentixol/melitracen (Deanxit) over serious neurological and psychiatric effects. It also started a review of hypersensitivity reports linked to immunoglobulin batches, covering all human normal immunoglobulin medicines. The comparison is useful. Routine PSUSAs, signal-driven reviews and referrals are separate tools. A maintenance result in one procedure says nothing about the others. The meeting dates also differ between the two source pages (AIFA cites 28–30 October, EMA's URL references 26–29 October), so check the official minutes before citing a date.

Who is affected

Holders of nationally authorised aprotinin products are the direct audience. They should check the published product list against their own portfolios and records. QPPVs and PV teams handling the other substances in the day's batch (gliclazide, tenoxicam, nitrofurantoin, cystine/pyridoxine) face the same housekeeping.

Teams with immunoglobulin or flupentixol/melitracen products have more to do. The new PRAC reviews may bring requests for data, including batch-level information on hypersensitivity cases. The records do not describe timelines or specific data requests, so these remain to be seen.

A related reminder comes from the US. FDA flagged the most serious recall category for four lots of Werfen's HemosIL AcuStar HIT-IgG(PF4-H) assay, used to detect heparin-induced thrombocytopenia antibodies. The reported negative bias may not be caught by routine calibration and quality control, and a supply interruption is expected. This is a device issue, not a drug-safety assessment, and nothing in the records links it to aprotinin. It does show that case assessment can depend on diagnostic tools, and teams should consider whether any suspected-reaction cases relied on affected lots.

What to watch

First, the detail of the Deanxit referral and the immunoglobulin review: scope, timetable and any interim communication to prescribers. Second, #MedSafetyWeek, running 2–8 November, which the Paul-Ehrlich-Institut and BfArM are backing with calls for professionals and patients to report suspected side effects. Companies that run their own awareness activity can align it with that week and make sure intake channels can cope with a rise in spontaneous reports.

Finally, quiet PSUSA outcomes still count as inspection-relevant evidence. Companies should be able to show when each outcome was received, who reviewed it and how the decision to act (or not) was recorded.